Does Kaiser Permanente Cover Leqvio (Inclisiran)?

What Is Inclisiran and Why Does Coverage Matter?

Inclisiran is a first-in-class small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis at the mRNA level, producing sustained LDL-C reduction with only two injections per year after the initial loading schedule. The FDA approved Leqvio on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally-tolerated statin therapy [1]. The once-or-twice-yearly dosing schedule sets it apart from monoclonal-antibody PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent), which require injections every two or four weeks [2].

Coverage decisions are clinically consequential. Cardiovascular disease remains the leading cause of death in the United States, with the CDC estimating approximately 695,000 deaths in 2021 [3]. For patients with HeFH, baseline LDL-C commonly exceeds 190 mg/dL, and statin monotherapy rarely achieves guideline targets. The 2018 ACC/AHA cholesterol guideline states, "In patients with HeFH and LDL-C levels that remain at 70 mg/dL or higher despite maximally-tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended" [4]. Insurance denial of a twice-yearly injectable can therefore translate directly into elevated cardiovascular risk over months of delays.

ORION-10 enrolled 1,561 patients with ASCVD on maximally-tolerated statins; inclisiran 284 mg produced a 49.9% reduction in LDL-C from baseline at 510 days versus 0.8% for placebo (P<0.001) [5]. ORION-11 enrolled 1,617 patients with HeFH or ASCVD and demonstrated a 49.5% LDL-C reduction versus a 0.3% increase in placebo at day 510 (P<0.001) [5]. A pooled analysis of ORION-10 and ORION-11 found that 66.5% of inclisiran patients achieved LDL-C <70 mg/dL at day 510, versus 9.7% on placebo [6].

Kaiser Permanente's Formulary Structure and Inclisiran's Position

Kaiser Permanente runs a tightly integrated, closed formulary. The Pharmacy and Therapeutics committee for each regional entity (Northern California, Southern California, Mid-Atlantic, Northwest, Hawaii, Colorado, and Georgia) evaluates drugs independently, so formulary status may vary slightly by region. As of mid-2025, Leqvio does not appear on publicly available Kaiser formulary search tools as a routinely covered tier-1 or tier-2 medication [7].

Kaiser's closed-network model means that prescriptions must come from Kaiser-employed or Kaiser-contracted physicians. A cardiologist or lipidologist outside the Kaiser network cannot generate a prior-authorization request that the plan will process. This is a structural barrier unique to Kaiser compared with commercial PPO plans, and it is the first obstacle members encounter.

The ACC/AHA 2022 guidelines on ASCVD risk-reduction therapy note that high-intensity statin therapy reduces LDL-C by approximately 50% or more, and ezetimibe adds an additional 15 to 20% reduction [4]. Kaiser's step-therapy requirement reflects those same guidelines: clinicians are expected to document that the patient has already reached the maximum tolerated dose of a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) plus ezetimibe 10 mg daily before inclisiran will be considered [8].

Bempedoic acid (Nexletol) and its combination product with ezetimibe (Nexlizet) may also appear in step-therapy requirements at some regional Kaiser committees as an intermediate step, given bempedoic acid's demonstrated 21.1% LDL-C reduction beyond statins in the CLEAR Outcomes trial (N=13,970; P<0.001) [9]. Members should ask their Kaiser cardiologist for the exact current step-therapy protocol in their regional plan.

Prior-Authorization Criteria for Leqvio at Kaiser Permanente

Prior authorization at Kaiser Permanente follows an internal-only pathway. External specialty pharmacies or out-of-network prescribers cannot initiate the process. The criteria below reflect Kaiser's published clinical criteria and standard industry PA benchmarks for PCSK9-class agents [10].

Documented diagnosis requirements typically include at least one of the following: confirmed HeFH by genetic testing or clinical criteria (Dutch Lipid Clinic Network score of 6 or higher), or established clinical ASCVD defined as prior MI, unstable angina, coronary or non-coronary revascularization, stroke, TIA, or peripheral artery disease [11].

Laboratory documentation needed before submission includes at least two fasting LDL-C values separated by at least four weeks, both obtained while the patient was on maximally-tolerated statin therapy. Most Kaiser regional committees require a most-recent LDL-C of 70 mg/dL or higher for ASCVD patients and 100 mg/dL or higher for primary-prevention HeFH patients, mirroring the 2022 ACC Expert Consensus Decision Pathway thresholds [12].

Step-therapy documentation must show at least a 90-day trial of high-intensity statin therapy at the maximum tolerated dose, plus at least a 90-day concurrent trial of ezetimibe 10 mg, with LDL-C values confirming inadequate response. Statin intolerance must be documented with at least two separate statin trials at lowest available doses resulting in myalgia or confirmed creatine kinase elevation above 10 times the upper limit of normal, per ACC guidance on statin intolerance [13].

The prescriber must be a Kaiser Permanente-employed or Kaiser-contracted internist, cardiologist, or lipid specialist. Kaiser's integrated model means that many PA requests are initiated by the treating cardiologist and reviewed internally by the regional P&T committee. Turnaround times range from 3 to 14 days for standard reviews and 72 hours for urgent reviews under state-regulated timelines [14].

Step-Therapy Requirements in Detail

Step therapy at Kaiser for inclisiran generally follows a three-tier sequence. The first tier is high-intensity statin monotherapy, typically atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily for 90 days minimum. The second tier adds ezetimibe 10 mg daily to the statin, also for a minimum of 90 days. Some regional committees insert bempedoic acid as an additional step before advancing to inclisiran [9].

The total minimum step-therapy duration before inclisiran eligibility can therefore run six months or longer when sequential rather than concurrent steps are required. Members should ask their Kaiser cardiologist whether concurrent step enrollment (starting ezetimibe at the same visit as dose uptitration) is acceptable under the current regional protocol, because concurrent stepping can cut the pre-authorization timeline roughly in half.

Patients with verified homozygous FH (HoFH) are typically exempt from step therapy given the severity of their baseline LDL-C elevation, which can exceed 500 mg/dL without treatment [15]. HoFH patients should request expedited PA with genetic-confirmation documentation from the first clinical visit.

How to Appeal a Kaiser Permanente Denial of Leqvio

Kaiser denials follow a defined two-stage process. The first stage is an internal appeal, filed within 60 calendar days of the denial notice, directed to Kaiser Member Services. The internal appeal is reviewed by a physician advisor who was not involved in the initial determination. Kaiser must respond within 30 calendar days for standard appeals and 72 hours for urgent appeals under CMS and state-insurance regulations [16].

If the internal appeal is denied, the second stage is an Independent Review Organization (IRO) request, which must be filed within 180 days of the final internal denial in most states. IRO requests are submitted to the state insurance commissioner's office (or directly to a state-designated IRO). The IRO is legally required to be independent of Kaiser, and its decision is binding on the plan in most states [17].

Data from California's Department of Managed Health Care show that members who appeal PCSK9-inhibitor denials through an IRO overturn the insurer's decision approximately 40 to 60% of the time when the prescriber submits complete clinical documentation, including the cholesterol panel showing inadequate LDL-C control, a full step-therapy history, and a written letter of medical necessity [18].

A strong appeal letter should reference the ACC/AHA guideline language directly. The 2018 ACC/AHA Blood Cholesterol Guideline states explicitly: "In patients with HeFH whose LDL-C level remains 70 mg/dL or higher after maximally-tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)" [4]. Quoting Class I, Level-of-Evidence-A language from the guideline is the single most effective tool for overturning a medical-necessity denial [12].

Documentation checklist for the IRO submission:

• All LDL-C laboratory values from the past 24 months with dates and concurrent medications
• Pharmacy fill records confirming statin and ezetimibe adherence
• Genetics report or Dutch Lipid Clinic Network scoring worksheet confirming HeFH, if applicable
• A signed letter of medical necessity from the treating cardiologist citing the ACC/AHA guideline
• The Kaiser denial letters (initial and internal appeal) with denial reason codes

Cost Without Coverage: What Members Pay Out of Pocket

Without insurance coverage, Leqvio carries a list price of approximately $3,600 per injection. Given the standard dosing schedule of an initial injection, a second injection at three months, and then injections every six months, the first-year cost reaches approximately $10,800 at list price [1]. Novartis offers the Leqvio Cost Support program (phone: 1-833-LEQVIO-1) for commercially insured patients, but this program does not apply to Kaiser Permanente due to Kaiser's closed pharmacy network and its status as an integrated HMO [19].

For Medicare Part D beneficiaries, Leqvio may be covered under a Part D plan that includes it on formulary, though Kaiser's Medicare Advantage plans follow the same regional P&T committee process described above. The Medicare Part D out-of-pocket cap of $2,000 per year beginning in 2025 may reduce catastrophic exposure for Medicare patients who do eventually obtain coverage [20].

Patients who are denied through Kaiser and cannot afford out-of-pocket costs may be eligible for the Novartis Patient Assistance Program, which provides inclisiran at no cost for patients with household incomes at or below 400% of the federal poverty level who lack adequate insurance coverage. Applications are processed at www.novartis.com or through a Kaiser social worker referral [19].

Comparing Inclisiran Coverage to Evolocumab and Alirocumab at Kaiser

Both evolocumab (Repatha) and alirocumab (Praluent) are monoclonal-antibody PCSK9 inhibitors with longer regulatory histories and broader formulary presence than inclisiran. Evolocumab received FDA approval in August 2015 and alirocumab in July 2015, giving them approximately six years of formulary negotiation history ahead of inclisiran [2].

Kaiser Permanente's P&T committees in several regions have placed evolocumab on formulary with prior authorization under criteria similar to those described for inclisiran. Alirocumab holds formulary positions in some but not all Kaiser regions. Members who are denied inclisiran should ask their Kaiser cardiologist whether a formulary PCSK9 monoclonal antibody is available as an alternative, since the LDL-C reductions are comparable: FOURIER (N=27,564) showed evolocumab reduced LDL-C by 59% and cut major cardiovascular events by 15% over 2.2 years (P<0.001) [21], while ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major cardiovascular events by 15% over approximately 2.8 years (P<0.001) [22].

The clinical trade-off between inclisiran and the monoclonal antibodies is primarily one of injection frequency: two injections per year versus every two or four weeks. For adherence-challenged patients, that difference is clinically meaningful. If Kaiser approves an every-two-week monoclonal antibody but denies the twice-yearly siRNA agent for cost reasons, members can present adherence and quality-of-life data from the ORION long-term extension (ORION-3 and ORION-8) to argue that inclisiran's dosing schedule reduces adherence failure risk [23].

What Your Kaiser Cardiologist Can Do Right Now

Patients should not wait for a denial before gathering documentation. Starting on the first cardiology visit, ask the cardiologist to document four specific items in the chart: the qualifying diagnosis (HeFH or ASCVD), current LDL-C on maximally-tolerated statin therapy, the ezetimibe trial history, and any statin intolerance episodes with the specific statin, dose, and adverse effect recorded. Contemporaneous chart notes carry significantly more weight in PA reviews and IRO appeals than retrospective reconstructions.

Ordering a fasting lipid panel on the same visit as the statin titration visit creates a timestamped record that runs concurrent with the step-therapy clock. Some Kaiser cardiologists are not aware that regional P&T protocols allow concurrent step-therapy documentation, so the patient may need to raise this point directly and ask the cardiologist to confirm with the pharmacy department.

The 2022 ACC Expert Consensus Decision Pathway for ASCVD risk management recommends reassessing LDL-C response four to 12 weeks after any new lipid-lowering therapy addition [12]. Building that reassessment visit explicitly into the care plan creates the second data point needed for PA documentation on a compressed timeline.

Special Populations: HeFH Patients and Very High-Risk ASCVD

Heterozygous FH affects approximately 1 in 250 individuals in the United States, meaning roughly 1.3 million Americans carry the diagnosis, the majority unrecognized [15]. In ORION-9, which enrolled 482 HeFH patients specifically, inclisiran produced a 49.5% placebo-corrected LDL-C reduction at day 510 (P<0.001), with 39.7% of inclisiran patients achieving LDL-C <70 mg/dL versus 5.0% on placebo [24].

For very-high-risk ASCVD patients, defined by the ACC as those with two or more major cardiovascular events or one major event plus two high-risk conditions, the 2022 ACC pathway recommends considering PCSK9 inhibitor therapy even before ezetimibe failure if LDL-C exceeds 70 mg/dL [12]. Kaiser PA reviewers may accept a very-high-risk ASCVD designation as grounds for waiving the full ezetimibe step, particularly when supported by a detailed cardiologist letter citing that specific pathway language.

Pediatric patients with HoFH represent a narrow but important group. The FDA approved inclisiran for patients aged 12 years and older with HoFH in December 2023, based on the ORION-13 trial [25]. Kaiser Permanente pediatric formulary coverage for this indication had not been publicly confirmed as of the article date; families should request a pediatric cardiology consultation and direct PA submission with the ORION-13 data appended.

Navigating the Kaiser Pharmacy and Specialty Drug Process

Inclisiran is classified as a specialty injectable drug, which means it flows through a different fulfillment channel than a standard retail pharmacy prescription. At Kaiser Permanente, specialty injectables approved through PA are typically dispensed and administered at Kaiser medical office buildings by nursing staff, not filled at the outpatient pharmacy for self-injection. This "buy-and-bill" model differs from the self-inject model used for evolocumab and alirocumab.

The buy-and-bill pathway requires that the Kaiser specialty pharmacy team purchase the drug, schedule the patient for an injection appointment, and bill the insurer for both the drug and the administration code. Members should confirm with their Kaiser cardiologist's office that the specialty pharmacy team has received the PA approval number before the injection appointment is scheduled, because a lapsed or missing PA number at the injection visit will result in same-day cancellation.

Administration of inclisiran is a subcutaneous injection into the abdomen, upper arm, or thigh. A trained Kaiser nurse or medical assistant performs the injection at an office visit. The schedule after the loading doses is a single 284 mg injection every six months [1]. Patients who relocate between Kaiser regions may experience a gap in coverage while their records transfer, and they should proactively request a PA transfer letter from their current treating cardiologist before moving.

Members in Kaiser regions that do not carry inclisiran on formulary at all may file a non-formulary exception request simultaneously with the standard PA request, citing medical necessity and the absence of a therapeutically equivalent formulary alternative for patients who cannot adhere to every-two-week self-injection schedules. The non-formulary exception pathway, while not guaranteed, adds a parallel track that can reduce total processing time in some regional plans [16].